We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Teva (TEVA) to Report Q1 Earnings: What's in the Cards?
Read MoreHide Full Article
Teva Pharmaceutical Industries Limited (TEVA - Free Report) will report first-quarter 2019 results on May 2 before market open. In the last reported quarter, the company delivered a negative earnings surprise of 5.36%.
Teva’s earnings surpassed expectations in three the last four quarters, with the average positive surprise being 18.24%.
This generic drugmaker’s shares have declined 0.4% this year so far against the industry’s increase of 6.6%.
Let’s see how things are shaping up for this announcement.
Factors to Consider
Teva reports under three segments — North America (United States and Canada), Europe and International Markets.
Pricing erosion in U.S. generics market, rapid erosion in sales of key multiple sclerosis drug, Copaxone and divestiture of some non-core assets are expected to hurt North America segment sales in the first quarter.
Importantly, sales of all other branded products Bendeka, Treanda, ProAir and Qvar declined in the past three quarters. The chances of sales trends improving in the first quarter are minimal. Moreover, introduction of generic versions of ProAir following patent expiration in 2018 may hurt sales of the branded drug in the first quarter.
Importantly, on the call, investors will be keen to know the sales numbers of Teva’s newly launched anti-calcitonin gene-related peptide (“CGRP”) drug, Ajovy (fremanezumab) injection, as a preventive treatment for migraine. Ajovy has been performing strongly since launch, enjoying growing demand due to its flexible dosing options - quarterly and monthly. An update is expected on the first-quarter conference call. Investors will also be interested to know how management plans to capture market share for Ajovy against Amgen and Lilly’s CGRPs, which were also launched last year.
Meanwhile, additional competition for Teva’s largest product, Concerta authorized generic, should also hurt generics sales in the quarter. Importantly, on the fourth-quarter call, the company had said that there were signs of stabilization in U.S. generic drug pricing. The company also said that the rate of sales erosion in the North American Generic business slowed significantly in the third and the fourth quarters of 2018 from second-quarter levels due to optimization of its generics product portfolio as well as product launches. The positive trend is expected to continue as several new generic products were launched in the first quarter.
An important recent generic launch was that of Mylan’s EpiPen (epinephrine) auto-injector for severe allergy treatment. Regarding its generic launch, Teva had said it expects to see normal supply levels by the end of first quarter/early second quarter. An update is expected on the call.
In Europe as well as International Markets, loss of revenues from divestitures/discontinued business activities is likely to hurt sales. The decline in sales of generic medicines and Copaxone is expected to continue, which can offset the positive impact of generic launches.
Cost savings from Teva’s aggressive restructuring initiatives are likely to provide some support to the bottom line. However, marketing costs are expected to be higher in the first quarter due to investments to support Ajovy’s launch.
Earnings Whispers
Our proven model does not conclusively show that Teva will beat on earnings this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. That is not the case here, as you will see below.
Earnings ESP: Its Earnings ESP +2.95% as the Zacks Consensus Estimate stands at 58 cents per share and the Most Accurate Estimate is pegged at 59 cents per share. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Teva has a Zacks Rank #5 (Strong Sell). We caution against Zacks Rank #4 (Sell) or 5 going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks to Consider
Here are some large drug stocks that have the right combination of elements to beat on earnings this time around:
GlaxoSmithKline (GSK - Free Report) has an Earnings ESP of +1.27% and a Zacks Rank #3. The company is slated to release results on May 1.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
Image: Bigstock
Teva (TEVA) to Report Q1 Earnings: What's in the Cards?
Teva Pharmaceutical Industries Limited (TEVA - Free Report) will report first-quarter 2019 results on May 2 before market open. In the last reported quarter, the company delivered a negative earnings surprise of 5.36%.
Teva’s earnings surpassed expectations in three the last four quarters, with the average positive surprise being 18.24%.
This generic drugmaker’s shares have declined 0.4% this year so far against the industry’s increase of 6.6%.
Let’s see how things are shaping up for this announcement.
Factors to Consider
Teva reports under three segments — North America (United States and Canada), Europe and International Markets.
Pricing erosion in U.S. generics market, rapid erosion in sales of key multiple sclerosis drug, Copaxone and divestiture of some non-core assets are expected to hurt North America segment sales in the first quarter.
Importantly, sales of all other branded products Bendeka, Treanda, ProAir and Qvar declined in the past three quarters. The chances of sales trends improving in the first quarter are minimal. Moreover, introduction of generic versions of ProAir following patent expiration in 2018 may hurt sales of the branded drug in the first quarter.
Importantly, on the call, investors will be keen to know the sales numbers of Teva’s newly launched anti-calcitonin gene-related peptide (“CGRP”) drug, Ajovy (fremanezumab) injection, as a preventive treatment for migraine. Ajovy has been performing strongly since launch, enjoying growing demand due to its flexible dosing options - quarterly and monthly. An update is expected on the first-quarter conference call. Investors will also be interested to know how management plans to capture market share for Ajovy against Amgen and Lilly’s CGRPs, which were also launched last year.
Meanwhile, additional competition for Teva’s largest product, Concerta authorized generic, should also hurt generics sales in the quarter. Importantly, on the fourth-quarter call, the company had said that there were signs of stabilization in U.S. generic drug pricing. The company also said that the rate of sales erosion in the North American Generic business slowed significantly in the third and the fourth quarters of 2018 from second-quarter levels due to optimization of its generics product portfolio as well as product launches. The positive trend is expected to continue as several new generic products were launched in the first quarter.
An important recent generic launch was that of Mylan’s EpiPen (epinephrine) auto-injector for severe allergy treatment. Regarding its generic launch, Teva had said it expects to see normal supply levels by the end of first quarter/early second quarter. An update is expected on the call.
In Europe as well as International Markets, loss of revenues from divestitures/discontinued business activities is likely to hurt sales. The decline in sales of generic medicines and Copaxone is expected to continue, which can offset the positive impact of generic launches.
Cost savings from Teva’s aggressive restructuring initiatives are likely to provide some support to the bottom line. However, marketing costs are expected to be higher in the first quarter due to investments to support Ajovy’s launch.
Earnings Whispers
Our proven model does not conclusively show that Teva will beat on earnings this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. That is not the case here, as you will see below.
Earnings ESP: Its Earnings ESP +2.95% as the Zacks Consensus Estimate stands at 58 cents per share and the Most Accurate Estimate is pegged at 59 cents per share. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Teva has a Zacks Rank #5 (Strong Sell). We caution against Zacks Rank #4 (Sell) or 5 going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks to Consider
Here are some large drug stocks that have the right combination of elements to beat on earnings this time around:
Allergan plc. has an Earnings ESP of +0.73% and a Zacks Rank #3. The company is slated to release results on May 7. You can see the complete list of today’s Zacks #1 Rank stocks here.
GlaxoSmithKline (GSK - Free Report) has an Earnings ESP of +1.27% and a Zacks Rank #3. The company is slated to release results on May 1.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
See their latest picks free >>